靶向巨噬细胞以增强CD47阻断引发的淋巴瘤清除并克服肿瘤诱导的免疫抑制
本研究探讨晚期非霍奇金淋巴瘤(NHL)对CD47阻断治疗耐药的原因,发现肿瘤相关巨噬细胞(TAM)吞噬能力受损是关键。通过高通量筛选FDA批准的抗癌小分子化合物,鉴定出紫杉醇可独立于其化疗细胞毒性直接增强巨噬细胞吞噬能力,与CD47靶向治疗联用可显著增强对晚期NHL的抗癌疗效。单细胞RNA测序分析显示紫杉醇诱导TAM亚群上调酪氨酸激酶信号基因,通过激活Src家族酪氨酸激酶信号促进对NHL细胞的吞噬,并阻止耐药相关TAM亚群积累。
要点
- 晚期NHL对CD47阻断治疗耐药与TAM吞噬能力受损相关。
- 紫杉醇通过激活巨噬细胞Src家族酪氨酸激酶信号增强吞噬,独立于其细胞毒性。
- 紫杉醇与CD47靶向治疗联用可增强对晚期NHL的疗效并重塑肿瘤微环境。
核心结论
- 靶向TAM以增强吞噬功能是NHL治疗的新策略,紫杉醇可增强CD47靶向治疗对晚期NHL的疗效。
- 紫杉醇通过激活巨噬细胞Src家族酪氨酸激酶信号促进对NHL细胞的吞噬。
- 紫杉醇可阻止仅在CD47靶向治疗耐药的晚期淋巴瘤中出现的TAM亚群积累,从而修改肿瘤微环境。
研究设计与样本
- 研究通过高通量筛选美国食品药品监督管理局(FDA)批准的抗癌小分子化合物,鉴定紫杉醇为吞噬促进剂。
- 采用单细胞RNA测序分析肿瘤微环境中的TAM亚群。
主要发现
- 晚期NHL对CD47靶向治疗耐药,归因于TAM吞噬淋巴瘤细胞的能力受损。
- 紫杉醇直接激发巨噬细胞吞噬能力,独立于其对NHL细胞的化疗细胞毒性。
- 紫杉醇与CD47靶向治疗联用显著增强对晚期NHL的抗癌疗效。
- 单细胞RNA测序显示紫杉醇诱导的TAM亚群上调酪氨酸激酶信号基因。
- 紫杉醇激活巨噬细胞Src家族酪氨酸激酶信号,促进对NHL细胞的吞噬。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tumor-associated macrophages (TAMs) are often the most abundant immune cells in the tumor microenvironment (TME). Strategies targeting TAMs to enable tumor cell killing through cellular phagocytosis have emerged as promising cancer immunotherapy. Although several phagocytosis checkpoints have been identified, the desired efficacy has not yet been achieved by blocking such checkpoints in preclinical models or clinical trials. Here, we showed that late-stage non-Hodgkin lymphoma (NHL) was resistant to therapy targeting phagocytosis checkpoint CD47 due to the compromised capacity of TAMs to phagocytose lymphoma cells. Via a high-throughput screening of the US Food and Drug Administration-approved anticancer small molecule compounds, we identified paclitaxel as a potentiator that promoted the clearance of lymphoma by directly evoking phagocytic capability of macrophages, independently of paclitaxel's chemotherapeutic cytotoxicity toward NHL cells. A combination with paclitaxel dramatically enhanced the anticancer efficacy of CD47-targeted therapy toward late-stage NHL. Analysis of TME by single-cell RNA sequencing identified paclitaxel-induced TAM populations with an upregulation of genes for tyrosine kinase signaling. The activation of Src family tyrosine kinases signaling in macrophages by paclitaxel promoted phagocytosis against NHL cells. In addition, we identified a role of paclitaxel in modifying the TME by preventing the accumulation of a TAM subpopulation that was only present in late-stage lymphoma resistant to CD47-targeted therapy. Our findings identify a novel and effective strategy for NHL treatment by remodeling TME to enable the tumoricidal roles of TAMs. Furthermore, we characterize TAM subgroups that determine the efficiency of lymphoma phagocytosis in the TME and can be potential therapeutic targets to unleash the antitumor activities of macrophages.
引用
- Cao X, Wang Y, Zhang W, et al. Targeting macrophages for enhancing CD47 blockade-elicited lymphoma clearance and overcoming tumor-induced immunosuppression. Blood. 2022. PMID: 35134139. doi:10.1182/blood.2021013901
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。